{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:32:05Z","timestamp":1786354325542,"version":"build-2736575974"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs), particularly antibodies targeting PD-1\/PD-L1 and CTLA-4, have reshaped the treatment landscape of lung cancers, most notably non-small cell lung cancer (NSCLC). Nevertheless, only a subset of patients achieve durable benefit due to primary and acquired resistance that arises from tumor-intrinsic factors (e.g., oncogenic drivers and adaptive signaling), tumor-extrinsic determinants in the tumor microenvironment (TME) (e.g., impaired T-cell infiltration and immunosuppressive myeloid populations), and the dynamic evolution of biomarkers. Accordingly, current clinical and translational efforts in lung cancer focus on rational combination strategies\u2014ICIs with chemotherapy, radiotherapy, and targeted agents (including RTK- and KRAS-pathway inhibitors)\u2014as well as alternative approaches that modulate antigen presentation, myeloid regulation, and cancer stemness. In this review, we define a lung cancer\u2013centered scope and summarize (i) established and emerging ICI-based regimens in lung cancer, (ii) mechanisms of resistance relevant to NSCLC and SCLC, (iii) biomarker integration for patient selection and monitoring, and (iv) future directions to optimize efficacy and safety through combinatory and alternative immunotherapeutic strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1878931","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:58:13Z","timestamp":1786352293000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint inhibitor-based combinatory and alternative strategies for immune treatment of lung cancers"],"prefix":"10.3389","volume":"17","author":[{"given":"Jun-Young","family":"Park","sequence":"first","affiliation":[{"name":"Molecular and Cellular Glycobiology Unit, Department of Biological Sciences, SungKyunKwan University","place":["Suwon, Gyunggi-Do, Republic of Korea"]},{"name":"Environmental Diseases Research Center, Korea Research Institute of Bioscience and Biotechnology","place":["Daejeon, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong-Hwan","family":"Kwak","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Glycobiology Unit, Department of Biological Sciences, SungKyunKwan University","place":["Suwon, Gyunggi-Do, Republic of Korea"]},{"name":"Department of Brewing, Dong-Eui Institute of Technology","place":["Busan, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biomedicine Imaging and Radiological Sciences, National Yang Ming Chiao Tung University","place":["Taipei, Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheorl-Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Glycobiology Unit, Department of Biological Sciences, SungKyunKwan University","place":["Suwon, Gyunggi-Do, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Sung","year":"2021","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/jci80004","article-title":"From mice to humans: Developments in cancer immunoediting","volume":"125","author":"Teng","year":"2015","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000376","article-title":"Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR\/ALK wild-type advanced non-small cell lung cancer","volume":"8","author":"Peng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22367","article-title":"Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers","volume":"129","author":"Hofman","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"B6","unstructured":""},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: Analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41698-020-0118-x","article-title":"Liquid biopsy mutation panel for non-small cell lung cancer: Analytical validation and clinical concordance","volume":"4","author":"Schwartzberg","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/0929867328666210806120347","article-title":"Research progress on the drug resistance of ALK kinase inhibitors","volume":"29","author":"Li","year":"2022","journal-title":"Curr Med Chem"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: Mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"biomark Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00418","article-title":"Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators","volume":"6","author":"Le Mercier","year":"2015","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213","article-title":"Mutational heterogenicity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)60958-2","article-title":"Anti-programmed-deathreceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"B16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000505478","article-title":"Nivolumab for metastatic cutaneous squamous cell carcinoma","volume":"12","author":"Oro-Ayude","year":"2020","journal-title":"Case Rep Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113618","article-title":"Focus on immune checkpoint PD-1\/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy","volume":"154","author":"Liu","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.8082","article-title":"Phytochemicals in regulating PD-1\/PD-L1 and immune checkpoint blockade therapy","volume":"38","author":"Zhang","year":"2024","journal-title":"Phytother Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_21011","article-title":"MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells","volume":"24","author":"Zhu","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: Current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: Learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.08.30","article-title":"Mechanisms of resistance to osimertinib","volume":"12","author":"Lazzari","year":"2020","journal-title":"J Thorac Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; Exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.9532","article-title":"Residual circulating tumor DNA (CtDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +\/- cetuximab","volume":"38","author":"Mack","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.xinn.2021.100103","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Cell"},{"key":"B29","unstructured":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.01.003","article-title":"Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance","volume":"14","author":"Shapira","year":"2011","journal-title":"Drug Resist Update"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-1590","article-title":"Molecular pathways: Regulation and therapeutic implications of multidrug resistance","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00351-8","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.21037\/atm-22-2436","article-title":"Two case reports of non-small cell lung cancer patients harboring acquired EGFR T790M-cis-C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy","volume":"10","author":"Song","year":"2022","journal-title":"Ann Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.106057","article-title":"Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs","volume":"128","author":"Zhao","year":"2022","journal-title":"Bioorg Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S453974","article-title":"MARIPOSA: Can amivantamab and lazertinib replace osimertinib in the front-line setting","volume":"15","author":"Brazel","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3233\/TUB-230034","article-title":"Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update","volume":"46","author":"Moes-Sosnowska","year":"2024","journal-title":"Tumour Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-022-01601-0","article-title":"Ceritinib is a novel triple negative breast cancer therapeutic agent","volume":"21","author":"Dong","year":"2022","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac087","article-title":"Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)","volume":"24","author":"Desai","year":"2022","journal-title":"Neuro Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-358","article-title":"Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients","volume":"13","author":"Weng","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-24-0658","article-title":"Targeting NTRK1 enhances immune checkpoint inhibitor efficacy in NTRK1 wild-type non-small cell lung cancer","volume":"84","author":"Smith","year":"2024","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864666","article-title":"NTRK fusion in non-small cell lung cancer: Diagnosis, therapy, and TRK inhibitor resistance","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"B47","article-title":"Tepmetko","year":""},{"key":"B48","article-title":"Tepmekto","year":"2021"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0283719","article-title":"Identifying optimal first-line immune checkpoint inhibitors-based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis","volume":"18","author":"Liu","year":"2023","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0417","article-title":"Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy","volume":"15","author":"Febres-Aldana","year":"2025","journal-title":"Cancer Discov"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102990","article-title":"Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer","volume":"139","author":"Paik","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611715","article-title":"Targeted therapeutic options in early and metastatic NSCLC-overview","volume":"30","author":"G\u00e1lffy","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114206","article-title":"Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer","volume":"208","author":"Park","year":"2024","journal-title":"Eur J Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36161","article-title":"Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants","volume":"10","author":"Jani","year":"2024","journal-title":"Heliyon"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1101\/gad.352081.124","article-title":"Undruggable KRAS\": druggable after all","volume":"39","author":"Cox","year":"2025","journal-title":"Genes Dev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41589-022-00985-w","article-title":"KRAS is vulnerable to reversible switch-II pocket engagement in cells","volume":"18","author":"Vasta","year":"2022","journal-title":"Nat Chem Biol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","article-title":"RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade","volume":"15","author":"Nokin","year":"2024","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14796694.2024.2430172","article-title":"Sotorasib for the treatment of locally advanced\/metastatic non-small cell lung cancer","volume":"21","author":"Higgins","year":"2025","journal-title":"Future Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00046","article-title":"Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRAS(G12C)-mutated non-small-cell lung cancer who have untreated CNS metastases","volume":"41","author":"Negrao","year":"2023","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.938746","article-title":"Editorial: Recent approval of sotorasib as the first targeted therapy for KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"Parums","year":"2022","journal-title":"Med Sci Monit"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-cancerbio-041621-012549","article-title":"Targeting KRAS G12C with covalent inhibitors","volume":"6","author":"Ostrem","year":"2022","journal-title":"Annu Rev Cancer Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2524311","article-title":"Adagrasib in the treatment of colorectal cancer","volume":"21","author":"Haddad","year":"2025","journal-title":"Future Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"3","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.09.025","article-title":"Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery","volume":"20","author":"Kothiwale","year":"2015","journal-title":"Drug Discov Today"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2016.11.009","article-title":"Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis","author":"Borza","year":"2017","journal-title":"Matrix Biol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103975","article-title":"DDR1-targeted therapies: current limitations and future potential","volume":"29","author":"Wu","year":"2024","journal-title":"Drug Discov Today"},{"key":"B76","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jconrel.2023.03.023","article-title":"SMO-CRISPR-mediated apoptosis in CD133-targeted cancer stem cells and tumor growth inhibition","volume":"357","author":"Pandey","year":"2023","journal-title":"J Control Release"},{"key":"B77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.62347\/VHYY2134","article-title":"CAIX-targeted PET imaging agents based on acetazolamide small molecule for clear cell renal cell carcinoma","volume":"15","author":"Li","year":"2025","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.941832","article-title":"The evolution of PRRT for the treatment of neuroendocrine tumors; what comes next","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2441-8_9","article-title":"Claudin-targeted suicide gene therapy for claudin-overexpressing tumor cells by using modified Clostridium perfringens enterotoxin (CPE)","volume":"2521","author":"Beier","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2653","article-title":"Abstract 2653: ABN501, a novel anti-claudin-3 antibody, shows potent anti-cancer activity in vitro and in vivo. POSTER PRESENTATIONS - PROFFERED ABSTRACTS| APRIL 04 2023","volume":"83","author":"Lee","year":"2023","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41419-022-05167-z","article-title":"Nuclear import of PTPN18 inhibits breast cancer metastasis mediated by MVP and importin beta2","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.8b14001","article-title":"In situ proapoptotic peptide-generating rapeseed protein-based nanocomplexes synergize chemotherapy for cathepsin-B overexpressing breast cancer","volume":"10","author":"Wang","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-023-00993-2","article-title":"Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1","volume":"20","author":"Kitagawa","year":"2023","journal-title":"Esophagus"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0093","article-title":"MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1878931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:58:15Z","timestamp":1786352295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1878931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":101,"alternative-id":["10.3389\/fimmu.2026.1878931"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1878931","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1878931"}}